Logo - International Journal of Pharmaceutical Compounding

Eosinophilic Esophagitis: Treatment with Oral Viscous Budesonide

Author(s):  Zur Eyal

Issue:  Jul/Aug 2012 - Volume 16, Number 4
View All Articles in Issue

Abstract:  Eosinophilic esophagitis is a clinicopathologic disease isolated to the esophagus. It is caused by immunologic reactions to ingested and inhaled allergans. Symptoms include regurgitation, vomiting, pain, anorexia, and dysphagia. Endoscopy with biopsy is currently the only reliable diagnostic test for eosinophilic esophagitis. The disease should remit with treatments of dietary exclusion, topical corticosteroids, or both. Oral viscous budesonide is one of the promising options of topical corticosteroid to treat eosinophilic esophagitis. Since there are no commercial medicines of oral viscous budesonide, it is solely a compounded medication. This article briefly discusses the properties of the disease and covers a few compounding possibilities to oral viscous budesonide.

Related Keywords: Eyal Zur, RPh, MBA, eosinophilic esophagitis, esophagus, immunologic reaction, allergens, dietary restrictions, topical administration, oral gel, viscous budesonide, topical corticosteroid, steroid gel, formulation

Related Categories: EAR NOSE THROAT, FORMULATIONS, ALLERGY/IMMUNOLOGY/INFLAMMATION

Purchase this article for download in electronic PDF format from IJPC at for $35 at:
http://www.ijpc.com/Products/ProductAddToCart.cfm?PID=3502

Search the entire IJPC archive by keyword, topic, or issue at:
http://ijpc.com/Products